Clinical Trial

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy

Study acronym: HiR+X
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the application of HiR (Zebtorizumab, Lenalidomide) + X (targeted drug) guided by NGS molecular typing, the aim is to assess the therapeutic efficacy and safety in newly diagnosed unfit or frail elderly patients with DLBCL aged ≥70 years, and to investigate the genetic subtypes that may benefit from HiR-X.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-02; most recent amendment 2025-03-16.
Trial Details
NCT Number NCT06758037
Lead Sponsor First Affiliated Hospital of Ningbo University
Conditions DLBCL, Diffuse Large B-Cell Lymphoma
Enrollment 50 participants
Start Date 2025-01-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-18